This Phase I proposal has the overall goal of developing improved cryosurgical treatment for prostate and other cancers by combining a drug (s) which triggers or promote gene activated cell death, or apoptosis, with traditional cryosurgical technique. Preliminary data are presented to support the hypothesis that cell death that occurs when cells are subjected to mild freezing insults (i.e. - minus oC) is a consequence of apoptosis. Anecdotal cryosurgical data have indicated that cancer cells in the middle of a tissue iceball created during cryosurgical procedures die immediately due to necrosis; whereas cells at the iceball periphery where temperatures approach 0oC die several days subsequent to cryoablation, while other cells in this periphery survive the freezing insult altogether. In vitro data provided show that cells frozen at minus 70oC die by necrosis; whereas at least 25% of the cells that die at minus 15 oC succumb via apoptosis. These observations lead to preliminary studies that showed that the addition of non-toxic levels of 5-fluorouracil (5-FU), a well-known apoptotic-inducing anticancer drug, greatly enhances the efficacy of cryo-induced cell killing. Based on these findings, it is proposed to determine if (1) the 5-FU pre-treatment enhancement of freezing-induced cell death is common to other cancer cell types; (2) the addition of other anticancer agents also enhances 5-FU's effect on freezing-induced cell death; (3) other chemotherapeutic compounds exhibit 5-FU-1 effects; (4) freezing-induced apoptosis is related to an increase in cytochrome c release from the mitochondria and/or upregulation of the tumor suppresser gene, p53 and (5) a novel double-label assay can be developed such that the relative number of apoptotic and necrotic cells can be quantified subsequent to an in vitro freezing protocol. Successful completion of these studies should provide basis for the development in Phase II of novel dual function cryoprobe devices that will also deliver chemotherapeutic agents to the tumor and thereby increase patient survival subsequent to cryosurgical treatments.

Proposed Commercial Applications

NOT AVAILABLE

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43RR016014-01
Application #
6054427
Study Section
Special Emphasis Panel (ZRG1-SSS-I (02))
Program Officer
Carrington, Jill L
Project Start
2000-06-15
Project End
2001-06-14
Budget Start
2000-06-15
Budget End
2001-06-14
Support Year
1
Fiscal Year
2000
Total Cost
$93,970
Indirect Cost
Name
Cell Preservations Services, Inc.
Department
Type
DUNS #
City
Owego
State
NY
Country
United States
Zip Code
13827
Clarke, Dominic M; Baust, John M; Van Buskirk, Robert G et al. (2004) Addition of anticancer agents enhances freezing-induced prostate cancer cell death: implications of mitochondrial involvement. Cryobiology 49:45-61
Gage, Andrew A; Baust, John G (2002) Cryosurgery - a review of recent advances and current issues. Cryo Letters 23:69-78
Clarke, D M; Baust, J M; Van Buskirk, R G et al. (2001) Chemo-cryo combination therapy: an adjunctive model for the treatment of prostate cancer. Cryobiology 42:274-85